Genetic and Clinical Characterization of Type 1 and 2 Narcolepsy in Adult and Pediatric Black and North African Populations
Key facts
- Who runs it
- Assistance Publique - Hôpitaux de Paris
- Where
- France1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Not yet recruiting
- People taking part
- 200 people, planned
- Started
- 30 Jan 2025
- Planned end
- 30 Jan 2026
- Type of study
- Observational, 2 groups
- Treatments tested
- saliva sampling
- Record updated
- 22 January 2025
Who can take part
- Age
- 6 years to 21 years
- Sex
- Women and men
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 9 criteriaShow less
Who can take part
- Narcolepsy patients:
- Individuals of black and North African origin diagnosed with NT1 or NT2
- Age ≥ 6 years
- Clinical confirmation of narcolepsy according to the criteria of the International Classification of Sleep Disorders (ICSD-3)
- Signature of informed consent by the adult patient or both holders of parental authority for minor patients; Control subjects:
- Volunteers without pathology related to the study from the same ethnic or related groups with the aim of reaching two matched control subjects for each case
- Age ≥ 6 years
- Signature of informed consent by the adult subject or both holders of parental authority for minor subjects
Who cannot take part
- Individuals unable to understand the protocol or unwilling to participate
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 6 and 21 years old?
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Narcolepsy type 1 (NT1) is a neurological disorder characterized by excessive daytime sleepiness, cataplexy, sleep paralysis, and hallucinations while awake. It results from the loss of orexin-producing neurons in the hypothalamus, leading to a deficiency of the neuropeptide orexin/hypocretin. Studies show differences in the clinical presentation of NT1 between Caucasian and African American populations, highlighting the importance of research into genetic and clinical characteristics specific to Black and North African populations.
Read full original descriptionShow less
A genetic study in these populations could identify novel genes associated with NT1 and NT2, providing crucial information for personalized diagnosis and treatment. This would fill a knowledge gap and promote more effective interventions for individuals of African descent, contributing to a better understanding of narcolepsy globally.
The 2 groups in the trial
- narcolepsy patients
50 narcolepsy patients will be included in the study at Robert Debré Hospital
Treatment: saliva sampling
- control patients
150 control patients will be included in the study at Robert Debré Hospital
Treatment: saliva sampling
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Fit questions
- Built from NCT06786377, who can take part
- Record updated
- 22 January 2025